Cardiovascular Risk in Climacteric Women: When to Begin the Hormone Treatment?

No abstract is available for this paper.

• Publication year

  2019

• Venue

  ISGE Series

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-3-030-11355-1_16
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol.

  2016cited by this paper
• Revised Global Consensus Statement on Menopausal Hormone Therapy

  2016cited by this paper
• Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future

  2013cited by this paper
• The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy.

  2013cited by this paper
• Global Consensus Statement on menopausal hormone therapy.

  2013cited by this paper
• The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective

  2012cited by this paper
• Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial

  2012cited by this paper
• Update in hormone therapy use in menopause.

  2011cited by this paper
• Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial.

  2011cited by this paper
• Scientific Statement: Postmenopausal Hormone Therapy

  2010cited by this paper
• Phosphodiesterase type-5 inhibitors and the reemerging HIV epidemic.

  2008cited by this paper
• Management of cardiovascular risk in the peri-menopausal woman: a consensus statement of European cardiologists and gynaecologists.

  2007cited by this paper
• Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

  2007cited by this paper
• Abstract 4041: Interleukin-10 Concentration and Coronary Heart Disease (CHD) Event Risk in the Estrogen Replacement and Atherosclerosis (ERA) Study

  2006cited by this paper
• Molecular and Cellular Basis of Cardiovascular Gender Differences

  2005cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease

  2000cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper

• No citing papers are available for this paper.